Session » Antiphospholipid Syndrome Poster (0069–0083)
-
Abstract Number: 0073
Anti-Domain 1 Antibody Fluctuation over Time in Patients with Persistently Positive Antiphospholipid Antibodies: Results from the Aps Action Clinical Database and Repository (“Registry”)
-
Abstract Number: 0074
Association of Anti-phospholipid Antibodies (aPL) with Poor Clinical Outcomes in Hospitalized Patients with COVID-19
-
Abstract Number: 0075
Endothelial Cell-activating Antibodies in COVID-19
-
Abstract Number: 0076
Predicting the Transitions Between Lupus Anticoagulant Status and Thrombosis in SLE Using a Multi-state Markov Model
-
Abstract Number: 0077
Association of Lupus Nephritis and Other Clinical Features with Antiphospholipid Antibody Positivity Among Patients with Systemic Lupus Erythematosus
-
Abstract Number: 0078
Frequency and Clinical Characteristics of Secondary Antiphospholipid Syndrome in Systemic Lupus Erythematosus: The Georgia Lupus Registry
-
Abstract Number: 0080
One Point Increase in the Initial Damage as Measured by the Damage Index for Antiphospholipid Syndrome Predicts Mortality in a Multi-Ethnic Group of Thrombotic Antiphospholipid Syndrome Patients
-
Abstract Number: 0081
Thrombin Generation Assay and Lupus Anticoagulant Identify Different Populations of Patients with Antiphospholipid Antibodies
-
Abstract Number: 0082
Association of Current Cigarette Smoking and Obesity with Antiphospholipid Antibodies and Thrombosis in 1216 International Patients Evaluated for Suspected Antiphospholipid Syndrome (APS)
-
Abstract Number: 0083
Cardiac Valve Surgery Outcomes in the Antiphospholipid Syndrome